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Objectives. We sought to identify the effects of endothelin (ET)
subtype-A (ETA)) receptor blockade during the development of
congestive heart failure (CHF) on left ventricle (LV) function and
contractility.
Background. Congested heart failure causes increased plasma
levels of ET and ETA receptor activation.
Methods. Yorkshire pigs were assigned to four groups: 1) CHF:
240 beats/min for 3 weeks; n 5 7; 2) CHF/ETA-High Dose: paced
for 2 weeks then ETA receptor blockade (BMS 193884, 50 mg/kg,
b.i.d.) for the last week of pacing; n 5 6; 3) CHF/ETA-Low Dose:
pacing for 2 weeks then ETA receptor blockade (BMS 193884,
12.5 mg/kg, b.i.d.) for the last week, n 5 6; and 4) Control: n 5 8.
Results. Left ventricle fractional shortening decreased with
CHF compared with control (12 6 1 vs. 39 6 1%, p < 0.05) and
increased in the CHF/ETA High and Low Dose groups (23 6 3 and
25 6 1%, p < 0.05). The LV peak wall stress and wall force
increased approximately twofold with CHF and remained in-
creased with ETA receptor blockade. With CHF, systemic vascular
resistance increased by 120%, was normalized in the CHF/ETA
High Dose group, and fell by 43% from CHF values in the Low
Dose group (p < 0.05). Plasma catecholamines increased fourfold
in the CHF group and were reduced by 48% in both CHF/ETA
blockade groups. The LV myocyte velocity of shortening was
reduced with CHF (32 6 3 vs. 54 6 3 mm/s, p < 0.05), was higher
in the CHF/ETA High Dose group (39 6 1 mm/s, p < 0.05), and
was similar to CHF values in the Low Dose group.
Conclusions. ETA receptor activation may contribute to the
progression of LV dysfunction with CHF.
(J Am Coll Cardiol 1998;32:1779–86)
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Activation of the endothelin (ET) receptor, particularly the
subtype A receptor (ETA), has been demonstrated to modu-
late a wide variety of biological processes including vascular
tone and myocardial contractile function (1–9). Increased
plasma endothelin levels have been identified in patients with
significant significant left ventricle (LV) dysfunction and he-
modynamic compromise (10–14). Accordingly, it has been
postulated that chronic activation of the ETA receptor may
contribute to the severity of the LV dysfunction in the setting
of congestive heart failure (CHF). Chronic pacing tachycardia
causes time-dependent changes in LV function and geometry
with progressive hemodynamic compromise (15–22). The pro-
gression of this cardiac disease process with respect to changes
in LV function and neurohormonal activation is similar to the
functional and neurohormonal spectrum observed in patients
with progressive CHF (10,13,23–26). More importantly, in-
creased plasma endothelin levels have been observed to occur
during the progression of pacing-induced CHF (15,18,19,22).
The overall goal of this project was to examine whether
institution of ETA receptor blockade during the progression of
pacing-induced CHF would significantly influence LV func-
tion.
There are several potential mechanisms by which ETA
receptor blockade may cause changes in LV pump function
with developing CHF. First, ETA receptor inhibition may
influence systemic vascular resistance properties and thereby
LV loading conditions. Second, ETA receptor blockade may
cause effects on LV contractile performance through local
modulation of myocardial ETA receptor activity. To determine
whether the effects of ETA receptor blockade were primarily
due to alterations in LV loading conditions, ETA receptor
blockade was initiated using two different dosing strategies that
would cause differential effects on systemic blood pressure. In
light of the significant changes in LV loading conditions and
neurohormonal status that occur with CHF, determination of
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whether and to what degree ETA receptor blockade influences
intrinsic properties of LV contractile function in vivo would be
problematic. Accordingly, the present project examined the
effects of ETA receptor blockade with the development of
pacing-induced CHF on isolated myocyte contractile function
and inotropic responsiveness.
Methods
Dose determination studies. To determine the dosage
strategy for ETA receptor blockade, 15 Yorkshire pigs (20 kg,
male) were chronically instrumented in order to measure
arterial blood pressure in the conscious state as described
previously (15). Following a recovery period of 7 to 10 days, the
animal was returned to the laboratory for an endothelin-1
pressor response study. For these studies, the animals were
sedated with diazepam (20 mg, p.o., Valium, Hoffmann-La
Roche, Nutley, NJ) and placed in a custom-designed sling that
allowed the animal to rest comfortably. All studies were
performed in the conscious state without additional use of
sedation. The vascular access port was entered using a 12-
gauge Huber needle (Access Technologies, Skokie, IL) and
basal, resting arterial pressure and heart rate were recorded.
Pressures from the fluid-filled aortic catheter were obtained
using an externally calibrated transducer (Statham P23ID,
Gould, Oxnard, CA). The electrocardiogram (ECG) and pres-
sure waveforms were recorded using a multichannel recorder
(Western Graphtec, FWR3701, Irvine, CA) as well as digitized
on computer for subsequent analysis at a sampling frequency
of 250 Hz (80386 processor, Zenith Data Systems, St. Joseph,
Michigan).
Following these baseline measurements, a bolus of
endothelin-1 (10 mg, Sigma, St. Louis, MO) was administered,
and heart rate and blood pressure recorded at 0 to 20 min
following endothelin-1 (ET-1) administration. The animals
were allowed to recover from the ET-1 pressor challenge for
48 h and then entered into the dose determination protocol.
For this portion of the study, 10 pigs were assigned to receive
either a high dose of the ETA receptor antagonist (50 mg/kg,
b.i.d.) or a low dose (12.5 mg/kg, b.i.d.) for 3 days. The animals
were returned to the laboratory and baseline blood pressure
and ET-1 pressor response studies repeated.
In the group receiving the low dose of the ETA receptor
antagonist, resting blood pressure was reduced from control
values (91 6 4 vs. 102 6 3 mm Hg, p , 0.05) and the ET-1
pressor response was reduced by approximately 50% (Fig. 1).
The high dose of the ETA receptor antagonist reduced basal
state mean arterial pressure from both control and low dose
ETA antagonist values (84 6 4, p , 0.05) and eliminated the
ET-1 pressor response (Fig. 1). In preliminary titration and
pharmacokinetic studies, the half-life of this ETA receptor
antagonist was computed to be approximately 6 h. Although
these studies provided the basis for dose selection in the
following pacing CHF studies, it must be recognized that the
ET pressor response is an indirect assessment of adequate ETA
receptor inhibition.
Experimental protocol and animal preparation. Following
the selection of the high and low dose of the ETA receptor
antagonist to be used, the second part of this study was
initiated. Age- and weight-matched pigs (Yorkshire, 20 to
21 kg) were randomly assigned to each of four groups: 1) rapid
atrial pacing (240 beats/min) for 3 weeks (n 5 7); 2) rapid
pacing for 2 weeks at which time the ETA receptor antagonist
was administered at 50 mg/kg, b.i.d.-p.o. for the final 7 days of
the pacing protocol (n 5 6); 3) rapid pacing for 2 weeks at
which time the ETA receptor antagonist was administered at
12.5 mg/kg, b.i.d.-p.o. for the final 7 days of the pacing protocol
(n 5 6); and 4) sham controls (n 5 8). The time point for
institution of either ETA receptor blockade was chosen based
upon past studies that have demonstrated significant LV pump
dysfunction and neurohormonal activation by day 14 of rapid
pacing (17,19,22).
Pacemakers were implanted or sham procedures performed
with animals anesthetized as described in the previous section,
and through a left thoracotomy, a shielded stimulating elec-
trode was sutured onto the left atrium, connected to a modified
programmable pacemaker (8329, Medtronic, Inc., Minneapo-
lis, MN) and buried in a subcutaneous pocket. Vascular access
Abbreviations and Acronyms
b-receptor 5 beta-adrenergic receptor
CHF 5 congestive heart failure
ET 5 endothelin
ETA 5 endothelin receptor subtype A
LV 5 left ventricle
Figure 1. The percent change in mean arterial pressure following
infusion of 10 mg of endothelin-1 (ET-1). Administration of 12.5 mg/kg
b.i.d. of the ETA receptor antagonist BMS-193884 reduced the ET-1
pressor response by approximately 50%. Administration of the ETA
receptor antagonist at 50 mg/kg b.i.d. virtually eliminated the ET-1
pressor response. These two doses of the ETA receptor antagonist
were then used to study the effects of ETA receptor blockade with the
development of pacing-induced CHF.
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ports were also implanted as described in the previous section.
Seven to 10 days following recovery from the surgical proce-
dure, a baseline LV ECG study was performed as described in
the following section, and the pacing protocols were initiated.
Cardiac auscultation and an electrocardiogram were per-
formed frequently during the pacing protocol to ensure proper
operation of the pacemaker and the presence of 1:1 conduc-
tion. The sham-operated controls were cared for in identical
fashion with the exception of the pacing protocol. All animals
were treated and cared for in accordance with the National
Institutes of Health “Guide for the Care and Use of Labora-
tory Animals” (National Research Council, Washington, DC,
1996).
LV function and hemodynamic measurements. On the
morning of day 21 of the study protocol and 2 h following the
AM drug dose (ETA receptor antagonist groups only), the
animals were brought to the laboratory, an ECG established,
and the pacemaker deactivated (pacing groups only). After a
30-min stabilization period, two-dimensional and M-mode
echocardiogram studies (ATL Ultramark VI, 2.25 MHz trans-
ducer, Bothell, WA) were used to image the LV from a right
parasternal approach (20,21). Arterial blood pressure was
simultaneously measured from the arterial access port. From
the arterial catheter, 30 cc of blood was drawn into chilled
tubes containing EDTA (1.5 mg/ml), and centrifuged (2,000g,
10 min, 4°C). The plasma was placed in separate tubes, frozen
in liquid nitrogen, and stored at 280°C until the time of
neurohormonal assay. A second arterial sample was drawn for
a room air blood gas determination. From the simultaneously
measured LV echocardiogram and aortic pressure recordings,
LV fractional shortening, LV peak wall stress, and wall force
were determined. The LV fractional shortening was calculated
as (end-diastolic dimension 2 end-systolic dimension)/end-
diastolic dimension and was expressed as a percent. Peak
circumferential wall stress was computed using a spherical
model: s(gm/cm2) 5 (PD/4 h[1 1 h/D]) 3 1.36; where P 5
arterial peak systolic blood pressure, D 5 minor axis dimen-
sion at end-diastole, and h 5 end-diastolic wall thickness.
Assuming a spherical geometry for the LV, net LV wall force
at peak systole was computed as: Force(g) 5 Pp r2 3 1.36;
where P is arterial systolic peak blood pressure and r is the
internal LV chamber radius (27,28).
To obtain a full hemodynamic profile, catheterization
studies were also performed under identical anesthetic
conditions. The animals were anesthetized with isoflurane
(0.5%/1.5 L/min) through a nonrecirculating anesthesia
circuit. A multilumened thermodilution catheter (7.5F, Baxter
Healthcare Corp., Irvine, CA) was positioned in the pulmonary
artery via the right external jugular vein. Using this catheter,
thermodilution-derived cardiac output, pulmonary artery pres-
sures, and pulmonary capillary wedge pressure were measured.
To ensure no damping of the arterial pressure trace occurred,
a 20-cm sheath was placed into the left carotid artery and
advanced to the ascending aorta for additional pressure mea-
surements. The ECG and pressure waveforms were recorded
and digitized as described in the previous section. Following
these measurements and maintaining a surgical plane of
anesthesia, a sternotomy was performed, and the heart quickly
extirpated and placed in a phosphate-buffered ice slush. The
great vessels were removed at the aortic and pulmonary valves,
and the LV was quickly weighed. The region of the LV free
wall perfused by the circumflex artery (5 3 5 cm) was excised
and prepared for myocyte isolation.
Neurohormonal assays. Plasma renin activity (PRA) was
determined by computing angiotensin I production using a
radioimmunoassay (NEA-026, New England Nuclear, Boston,
MA). The interassay variation for the PRA measurements was
15%. For the ET assays, the plasma was first eluted over a
cation exchange and ET determined by high sensitivity radio-
immunoassay as described previously by this laboratory (18).
The interassay variation was 10% and the intraassay variation
was 9% for the ET radioimmunoassay procedure. In prelimi-
nary studies, the ETA antagonist (BMS-193884) was added to
normal plasma at a final concentration of 5 mM and the ET
assay performed. The variation in ET levels between normal
plasma and plasma spiked with the ETA antagonist was less
than 10%. Thus, the presence of the ETA receptor antagonist
in plasma samples did not interfere with the ET immunoassay
procedure. Plasma norepinephrine and epinephrine were mea-
sured using high performance liquid chromatography and
normalized to pg/ml of plasma.
Myocyte isolation and contractile function. The LV iso-
lated myocytes were prepared as described previously (17–21).
Isolated LV myocyte contractility was then examined using
computer-assisted video-microscopy (19–21). Variables com-
puted from the LV myocyte contraction profiles include per-
cent shortening, velocity of shortening, velocity of relengthen-
ing, time to peak contraction, and duration of contraction.
Through the use of increased extracellular Ca21 or beta-
adrenergic receptor (b-receptor) stimulation, the capacity of
the myocyte to respond to an inotropic stimulus can be
examined (17–21). The development of CHF in patients and
animals has been reported to be associated with abnormalities
in inotropic responsiveness (16,21,25). Accordingly, myocyte
response to a specific inotropic stimulus was determined in all
four treatment groups. Following the determination of base-
line contractile function, myocyte contractile function was
examined in the presence of either 8 mM extracellular Ca21,
25 nM isoproterenol (-Isoproterenol, Sigma, St. Louis, MO) or
200 pM ET-1 (E7764, Sigma, St. Louis, MO). The concentra-
tions for isoproterenol and ET-1 used in this study had been
demonstrated previously to provide near maximal contractile
response for this myocyte preparation (18,21).
Data analysis. Indices of LV and myocyte function were
compared among the treatment groups using analysis of vari-
ance. For the myocyte function studies, an analysis of variance
(ANOVA) using a randomized block split-plot design was
employed. The treatment effects were pacing and ETA recep-
tor antagonist therapy. Each pig was considered a complete
block. Thus, the numbers of myocytes studied from each
animal were considered repeated observations within each
block. If the ANOVA revealed significant differences, pairwise
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tests of individual group means were compared using Bonfer-
roni probabilities. For comparisons of neurohormonal profiles,
the Student-Newman-Keuls’ test was employed. All statistical
procedures were performed using the BMDP statistical soft-
ware package (BMDP Statistical Software Inc., Los Angeles,
CA). Results are presented as mean 6 standard error of the
mean (SEM). Values of p , 0.05 were considered to be
statistically significant.
Results
LV function with pacing CHF: Effects of short-term ETA
receptor blockade. Baseline LV fractional shortening in the 27
pigs prior to randomization into the study protocol was 39.5 6
0.6% and LV end-diastolic dimension was 3.4 6 0.7 cm; these
values were unchanged in the time-matched sham control
animals at the conclusion of the study protocol (Table 1). In
the chronic rapid-pacing groups, which underwent ETA recep-
tor blockade with either a high or a low dose of receptor
antagonist, resting heart rates were lower when compared to
the rapid-pacing-only group. In the rapid-pacing group receiv-
ing the low dose of ETA receptor antagonist, mean arterial
pressure was higher than in the rapid-pacing-only group. In the
high dose ETA receptor blockade group, mean arterial pres-
sure was similar to the untreated rapid-pacing group. The LV
end-diastolic dimension was similar in the rapid-pacing groups
receiving either the high or low dose of ETA receptor antag-
onist when compared to the rapid-pacing-only group. In the
rapid-pacing groups receiving either the high or low dose of
ETA receptor antagonist, LV fractional shortening was in-
creased by 100% from rapid-pacing-only values. Rapid pacing
and ETA low-dose receptor blockade was associated with a
significant reduction in LV peak systolic wall stress when
compared to rapid-pacing-only values. Cardiac output was
significantly increased in the rapid-pacing and ETA receptor
blockade groups when compared to rapid-pacing-only values,
but remained lower than sham control values. Pulmonary
vascular resistance was reduced by nearly 50% in the rapid-
pacing and ETA receptor blockade groups when compared to
rapid-pacing-only values. Pulmonary vascular resistance was
lower in the rapid-pacing and high dose ETA receptor block-
ade group when compared to the low dose ET receptor
blockade group, but this did not reach statistical significance
(p 5 0.065). Systemic vascular resistance fell by approximately
50% in the rapid-pacing and ETA receptor blockade groups
when compared to the rapid-pacing-only group and was not
different from the sham control group. Systemic vascular
resistance was lower in the high dose ETA blockade group
when compared to the low dose ETA receptor blockade group,
but this did not reach statistical significance (p 5 0.104).
However, dose-dependent relationships of ETA receptor
blockade were not evaluated in the present study owing to the
fact that direct assessment of adequate ETA receptor inhibi-
tion was not directly measured in the pacing CHF animals.
Neurohormonal profiles with pacing CHF: Effects of short-
term ETA blockade. Plasma norepinephrine increased by four-
fold and epinephrine also increased fourfold with chronic rapid
pacing when compared to control values (Table 1). In the
chronic rapid-pacing group, plasma ET levels increased by
280% and plasma renin activity increased by 333% when
compared to the control group. In both the high and low dose
ETA receptor blockade and rapid-pacing groups, plasma nor-
epinephrine and epinephrine values were significantly lower
than rapid-pacing-only values. Plasma norepinephrine concen-
Table 1. Left Ventricular Function, Hemodynamics and Neurohormonal Profiles With Rapid-Pacing
Heart Failure: Effects of Endothelin Receptor Blockade During the Progression of Heart Failure
Control Rapid Pacinga
Rapid Pacing and
ET-block–Highb
Rapid Pacing and
ET-block–Lowc
Resting heart rate (beats/min) 114 6 4 165 6 4* 147 6 7*† 147 6 3*†
Mean arterial pressure (mm Hg) 90 6 2 70 6 5* 74 6 2* 80 6 3*†
LV end-diastolic dimension (cm) 3.5 6 0.6 5.4 6 0.1* 5.6 6 0.3* 5.0 6 0.2*
LV fractional shortening (%) 38.6 6 1.3 12.3 6 0.8* 22.7 6 3.1*† 24.6 6 1.2*†
LV peak wall stress (g/cm2) 153 6 7 323 6 32* 293 6 23* 265 6 14*†
LV peak wall force (g 3 103) 1.49 6 0.06 2.83 6 0.30* 3.18 6 0.28* 2.64 6 0.19*
LV end-diastolic wall thickness (cm) 0.74 6 0.02 0.48 6 0.02* 0.57 6 0.02*† 0.56 6 0.03*†
P. capillary wedge pressure (mm Hg) 8 6 1 28 6 3* 22 6 2*† 22 6 3*†
Pulmonary artery pressure (mm Hg) 14 6 3 37 6 4* 28 6 5*† 37 6 2*
Cardiac output (L/min) 2.43 6 0.18 0.93 6 0.12* 1.95 6 0.09*† 1.72 6 0.19*†
Pulmonary vascular Res. (d.s.cm25) 427 6 51 3275 6 440* 1253 6 233*† 1758 6 160*†
Systemic vascular Res. (d.s.cm25) 3149 6 223 6934 6 940* 3152 6 150† 3959 6 398*†
Plasma norepinephrine (pg/ml) 815 6 219 6864 6 1160* 2363 6 706*† 3514 6 705*†
Plasma epinephrine (pg/ml) 422 6 199 1648 6 446* 576 6 322† 935 6 266†
Plasma endothelin (fmol/ml) 2.7 6 0.4 10.4 6 1.6* 8.5 6 0.5* 14.1 6 3.1*
Plasma renin activity (ng/ml/hr) 2.7 6 0.5 13.4 6 0.2* 10.1 6 0.4* 10.9 6 1.07*
Sample size (n) 8 7 6 6
All values presented as mean 6 SEM. *p , 0.05 vs. control. †p , 0.05 vs. rapid pacing only. aRapid Pacing: 21 days
of pacing; 240 beats/min. b50 mg/kg, b.i.d. starting at day 14 of pacing. c12.5 mg/kg, b.i.d. starting at day 14 of pacing.
d.s.cm25: dyne s cm25.
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trations in the ETA receptor blockade and rapid-pacing groups
remained higher than control values, but epinephrine values
were not significantly different from controls (p 5 0.35). No
dose-dependent differences occurred in plasma cat-
echolamines with respect to either the high or low ETA
receptor antagonist group (p 5 0.45). Plasma ET levels were
significantly increased in the ETA receptor blockade and
rapid-pacing groups when compared to controls, but were not
different from rapid-pacing-only values. In the low dose ETA
blockade group, plasma ET levels appeared higher than rapid-
pacing-only values, but this did not reach statistical significance
(p 5 0.33). Plasma renin activity was increased in both ETA
receptor blockade and rapid-pacing groups when compared to
control values, but was similar to rapid-pacing-only values.
Myocyte function with pacing CHF: Effects of short-term
ETA receptor blockade. A total of 1,187 isolated myocytes
were studied in the control group, 1,007 in the rapid-pacing-
only group, 854 in the rapid-pacing and high dose ETA
blockade group, and 853 in the rapid-pacing and low dose ETA
blockade group (Table 2). In the chronic rapid-pacing group,
isolated myocyte length was increased and percent and velocity
of shortening were significantly reduced. In both rapid-pacing
and ETA receptor blockade groups, myocyte length was similar
to rapid-pacing-only values. In the rapid-pacing and high dose
ETA blockade group, a small but significant increase in myo-
cyte velocity of shortening and relengthening was observed
when compared to rapid-pacing-only values. In the rapid-
pacing and high dose ETA blockade group, myocyte percent
shortening was higher than rapid-pacing-only values, but this
did not reach statistical significance (p 5 0.08). In the rapid-
pacing and low dose ETA blockade group, myocyte function
was not different from rapid-pacing-only values.
The b-receptor stimulation with isoproterenol increased
myocyte function from basal values in all groups (Table 2). In
the presence of isoproterenol, myocyte function remained
significantly lower in all rapid-pacing groups when compared
to the control group. In the high dose ETA receptor blockade
group, myocyte function was higher following b-receptor stim-
ulation when compared to rapid-pacing-only values. In the low
dose ETA receptor blockade group, myocyte velocity of short-
Table 2. Isolated Myocyte Contractile Function With Rapid-Pacing Heart Failure: Effects of
Endothelin Receptor Blockade
Baseline
25 nM
Isoproterenol
8 mM
Calcium
200 pM
Endothelin-1
RESTING LENGTH (mm)
Control 142 6 1 140 6 2 129 6 4# 134 6 3
Rapid Pacinga 166 6 5* 158 6 5* 156 6 5* 157 6 5*
Rapid Pacing and ET-block–Highb 175 6 4* 165 6 4* 164 6 6* 168 6 5*
Rapid Pacing and ET-block–Lowc 173 6 5* 166 6 5* 167 6 9* 163 6 4*
PERCENT SHORTENING (%)
Control 4.5 6 0.2 8.6 6 0.3# 8.7 6 0.7# 5.7 6 0.3#
Rapid Pacinga 2.4 6 0.2* 4.7 6 0.4*# 6.3 6 0.3*# 2.0 6 0.1*
Rapid Pacing and ET-block–Highb 2.9 6 0.2* 6.1 6 0.7*†# 5.8 6 0.5*# 2.6 6 0.3*
Rapid Pacing and ET-block–Lowc 2.6 6 0.2* 5.2 6 0.3*# 6.1 6 0.9*# 2.3 6 0.2*
SHORTENING VELOCITY (mm/s)
Control 54 6 3 157 6 7# 125 6 16# 70 6 5#
Rapid Pacinga 32 6 3* 84 6 6*# 91 6 7*# 23 6 2*#
Rapid Pacing and ET-block–Highb 39 6 1*† 128 6 14*†# 87 6 12*# 32 6 3*†
Rapid Pacing and ET-block–Lowc 35 6 3* 106 6 5*†# 89 6 20*# 28 6 2*
RELENGTHENING VELOCITY (mm/s)
Control 60 6 3 148 6 10# 146 6 17# 75 6 6#
Rapid Pacinga 30 6 3* 61 6 5*# 87 6 9*# 20 6 2*#
Rapid Pacing and ET-block–Highb 41 6 3*† 99 6 14*†# 90 6 10*# 33 6 4*†
Rapid Pacing and ET-block–Lowc 35 6 4* 75 6 5*# 95 6 21*# 27 6 3*
TIME TO PEAK CONTRACTION (ms)
Control 264 6 13 196 6 9# 236 6 14 276 6 23
Rapid Pacinga 256 6 5 202 6 5# 233 6 7# 275 6 22
Rapid Pacing and ET-block–Highb 263 6 13 184 6 5†# 220 6 13# 282 6 14
Rapid Pacing and ET-block–Lowc 256 6 5 189 6 4†# 222 6 13# 280 6 6#
TOTAL CONTRACTION DURATION (ms)
Control 502 6 12 402 6 17# 420 6 26# 520 6 31
Rapid Pacinga 504 6 10 471 6 11* 473 6 22 575 6 14#
Rapid Pacing and ET-block–Highb 505 6 24 412 6 17†# 457 6 38 535 6 22
Rapid Pacing and ET-block–Lowc 514 6 18 456 6 11*# 456 6 36 561 6 17
All values presented as mean 6 SEM. *p, 0.05 vs. control; †p , 0.05 vs. rapid pacing only; #p , 0.05 vs. baseline.
aRapid Pacing: 21 days of pacing; 240 beats/min. b50 mg/kg, b.i.d. at day 14 of pacing. c12.5 mg/kg, b.i.d. at day 14 of
pacing.
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ening was increased following b-receptor stimulation when
compared to rapid-pacing-only values. With increased extra-
cellular Ca12, myocyte contractile function was significantly
lower in all rapid-pacing groups when compared to control
values. In contrast to b-receptor stimulation, there was no
difference in myocyte function in the presence of increased
extracellular Ca12 between the rapid-pacing-only group and
either ETA receptor blockade groups. In the presence of ET-1,
myocyte contractile function significantly increased from base-
line values in the control group. In marked contrast, in the
rapid-pacing-only group, ET-1 resulted in a significant decline
in myocyte contractile function from baseline values. In both
rapid-pacing and ETA receptor blockade groups, no significant
change occurred in myocyte contractile function from baseline
values in the presence of ET-1.
Discussion
It has been postulated that increased plasma levels of the
potent vasoactive peptide endothelin-1, through activation of
the ETA subtype receptor, may contribute to the LV dysfunc-
tion and exacerbation of symptoms in congestive heart failure
(CHF) (6,10–14,29–31). Accordingly, the overall goal of the
present study was to determine whether ETA receptor block-
ade initiated during the progression of pacing-induced CHF
would improve indices of LV pump function and to define
potential mechanisms for these effects. The significant findings
of the present study were threefold. First, ETA receptor
blockade initiated during the progression of pacing-induced
CHF reduced pulmonary and systemic vascular resistance and
improved LV pump function. Second, ETA receptor blockade
instituted during the progression of pacing CHF reduced
circulating catecholamines from pacing CHF values, but did
not reduce plasma ET or renin activity. Third, ETA receptor
blockade appeared to confer protective effects on myocyte
contractile function and the capacity to respond to an inotropic
stimulus, but these effects were most apparent using a high
dose of ETA receptor blockade. However, the adequacy of
ETA receptor inhibition was not directly assessed in the pacing
CHF groups and therefore direct assessment of dose depen-
dency for ETA receptor blockade could not be addressed.
Nevertheless, the results from the present study suggest that
contributory mechanisms for the improved LV pump function,
which was observed with the institution of ETA receptor
blockade during the development of pacing-induced CHF,
include a reduction in systemic vascular resistance, reduced
sympathetic activity and potentially protective effects on myo-
cyte contractile performance.
Left ventricular function and vascular resistive properties
with ETA receptor blockade. This laboratory has demon-
strated previously that chronic rapid pacing in pigs caused
progressive LV dilation and pump dysfunction, and severe
CHF occurred after a 3-week pacing period (17–21). The ETA
receptor blockade during the last 7 days of chronic pacing did
not affect the degree of LV dilation, but did significantly
improve LV pump function. A likely contributory factor for the
improved LV pump function with ETA receptor blockade in
this pacing CHF model was reduced systemic vascular resis-
tance. Moreover, results from the present study suggest that
the reduction in systemic vascular resistance with ETA recep-
tor blockade was dose dependent. Past experimental and
clinical studies have examined the effects of acute ET receptor
blockade initiated following the development of CHF (11,29–
31). For example, Kiowski et al. (11) reported that acute
administration of the nonselective ET receptor antagonist
bosentan significantly reduced systemic vascular resistance in
patient with CHF. In a canine model of CHF due to coronary
microembolization, IV administration of bosentan reduced
systemic vascular resistance and increased indices of LV pump
function (31). More recently, this laboratory demonstrated
that ETA receptor blockade instituted at the onset of chronic
rapid pacing in rabbits improved indices of LV and myocyte
function (19). Results from the present study build upon these
past reports in several important ways. First, results from the
current study demonstrated that selective ETA receptor block-
ade instituted during the evolution of a CHF process improved
LV pump function. Second, these beneficial effects of ETA
receptor blockade on LV pump performance with developing
CHF could be achieved using a dose of ETA receptor that did
not significantly compromise mean arterial pressure and cause
hemodynamic instability.
The institution of ETA receptor blockade during the pro-
gression of pacing CHF attenuated the degree of LV myocar-
dial wall thinning but did not prevent the LV chamber dilation,
which invariably occurs in this CHF model (15–21). Thus, the
relative improvement in LV pump function with ETA receptor
blockade was not associated with a proportional reduction in
LV peak wall stress. Moreover, the LV peak wall force, an
index of the load under which the LV must contract against
(27,28), was increased with pacing CHF and was not reduced
with ETA receptor blockade. Hence, the improved LV pump
function with ETA receptor blockade must have been due to
additional contributory factors, rather than primarily by a
reduction in LV loading conditions. Potential contributory
mechanisms for the improved LV pump function with ETA
receptor blockade during the progression of pacing CHF
include a reduction in basal resting heart rate, reduced sym-
pathetic activation and potential improvements in myocyte
contractile processes.
Several past studies have demonstrated that ETA receptor
activation may play an important role in modulating pulmo-
nary vascular resistance in patients with CHF (10,14). In the
present study, there was a significant reduction in pulmonary
vascular resistance with ETA receptor blockade with pacing
CHF. In patients with CHF, a relationship between circulating
levels of ET and the degree of pulmonary vascular resistance
has been reported (10,14). Kiowski et al. (11) reported that
acute administration of the nonselective ET receptor antago-
nist bosentan significantly reduced pulmonary vascular resis-
tance in patients with CHF. Results from the present study
suggest that modulation of ETA receptor activity within the
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pulmonary circuit may be an important strategy for reducing
pulmonary vascular resistance with developing CHF.
Neurohormonal system activity with ETA receptor block-
ade. Increased circulating levels of catecholamines, endothe-
lin and elevated plasma renin activity commonly occur with the
development of severe CHF (10–14,23,25). In the present
study and consistent with past reports, (15–19,22) pacing-
induced CHF was accompanied by a similar profile of neuro-
hormonal activation. Institution of ETA receptor blockade
during the progression of pacing CHF reduced plasma cate-
cholamine values but had no effect on plasma renin activity.
The relative reduction in plasma catecholamines was observed
with ETA receptor blockade instituted at either the high or low
dose. A similar reduction in plasma catecholamines has been
reported following the induction of angiotensin converting
enzyme inhibition in the setting of CHF (17,23). Whether and
to what degree ET-1 production and ETA receptor activation
directly contributed to sympathetic activation and enhanced
catecholamine production in the setting of CHF remains to be
established. The persistent increase in plasma renin activity
observed with ETA receptor blockade and chronic rapid pacing
may have been secondary to a relative reduction in renal
perfusion pressure. In addition, an interaction has been re-
ported to occur in vitro between ET receptor density and
angiotensin-II production (31). The specific interactive effects
of the renin-angiotensin system and ETA receptor activity in
the setting of CHF were beyond the scope of the present study
and warrant further investigation. The ETA receptor blockade
for the final 7 days of chronic rapid pacing did not increase
circulating levels of immunoreactive plasma ET above those
observed in the untreated CHF group. The persistent eleva-
tions in plasma ET levels that were observed in the present
study following ETA receptor blockade were probably due, at
least in part, to interruption of an endothelin/ETA receptor
feedback loop. In light of these findings, the influence of ETA
receptor blockade on ET synthetic and degradative pathways
in the setting of CHF warrants further study.
Myocyte function and ETA blockade with pacing CHF. In
the present study, contractile function was examined from
myocytes isolated from the LV free wall served by the circum-
flex coronary artery. Myocyte contractility has been examined
previously from regions of the LV served by both the left
anterior descending and the circumflex coronary arteries in
both normal and pacing CHF preparations (32). This past
study demonstrated that no significant differences existed in
contractile performance from myocytes harvested from these
two regions of the LV (32). In the present study, short-term
ETA receptor blockade had minimal effects on basal contrac-
tile function when compared to pacing CHF only values. With
the high dose of ETA receptor antagonist, baseline steady-state
contractile function was improved by 28% when compared to
pacing CHF values. In a past report, chronic ETA receptor
blockade significantly improved LV myocyte contractility and
was associated with improved LV pump function in a pacing
rabbit model of CHF (19). Thus, in the present study, a
contributory component for the improved LV pump function
using the high dose of ETA receptor antagonist may have been
an improvement in LV myocyte contractile performance.
In the present study, ETA receptor blockade instituted
during the last week of chronic rapid pacing provided a
protective effect on myocyte b-adrenergic responsiveness. It
has been proposed that one mechanism for the changes in the
b-receptor system with severe CHF is that the elevated circu-
lating catecholamines result in chronic b-receptor activation
with subsequent receptor downregulation as well as alterations
in the transduction system (21,24). The ETA receptor blockade
during chronic rapid pacing reduced plasma catecholamine
levels from rapid-pacing-only values. Thus, a contributory
mechanism for the improved myocyte beta-adrenergic respon-
siveness with ETA receptor blockade was reduced circulating
catecholamine levels and preservation of the b-receptor trans-
duction system. In the ETA receptor blockade and rapid-
pacing groups, myocyte response to extracellular Ca12 re-
mained unchanged from the pacing CHF group. This provides
further evidence that ETA receptor blockade had no effect on
myofilament sensitivity to Ca12 or Ca12 homeostatic mecha-
nisms, but rather had a beneficial protective effect on sar-
colemmal transduction systems as well as cyclic adenosine
monophosphate (cAMP)-dependent processes.
Past studies have demonstrated that ET-1 may influence
myocyte contractile function through a number of intracellular
mechanisms (4–9). With the development of pacing-induced
CHF, ET-1 caused a negative contractile response and was
consistent with a past report from this laboratory (18). More
importantly, it has been demonstrated previously that the
predominant myocyte ET receptor is the ETA receptor subtype
and that myocyte ETA receptor density remained unchanged
with the development of pacing CHF (18). With the institution
of ETA receptor blockade at both the high and low dose during
the development of pacing CHF, a persistent negative effect on
myocyte contractile response was observed in the presence of
ET-1. These myocyte contractile function measurements were
performed in vitro in the absence of extracellular hormonal
influences. Moreover, although the isolated LV myocytes were
isolated and run through several changes of cell culture media
prior to study (18,20), whether and to what degree the ETA
receptor antagonist remained bound to myocyte sarcolemmal
receptors was not directly assessed.
Study limitations. An important limitation of the present
study was that the adequacy of ETA receptor blockade was not
directly measured in the pacing CHF groups. This prevented
conclusions being drawn regarding the dose dependency of
ETA receptor inhibition and the duration of the effects of ETA
receptor blockade in this model of CHF. Furthermore,
whether the ETA receptor inhibitory profiles obtained in the
normal preparations were maintained in the pacing CHF state
could not be addressed. At the conclusion of the 3-week pacing
protocol, the LV was harvested for myocyte preparations.
Thus, whether the effects of ETA receptor blockade would
persist after an adequate washout period remains uncertain.
The present project employed a model of chronic rapid pacing
that produced changes in LV functional and neurohormonal
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characteristics similar to that of the clinical spectrum of CHF
(15–22). Using this animal model of CHF provided an oppor-
tunity to determine the effects of ETA receptor blockade in the
absence of confounding influences that might be encountered
in clinical studies. However, it must be recognized that any
animal model will not fully represent the complex clinical
spectrum of CHF. Specifically, the changes in LV myocardial
structure that occur with pacing-induced CHF are not similar
to clinical forms of CHF owing to chronic ischemia or hyper-
tensive disease. Nevertheless, the present study demonstrated
that institution of ETA receptor blockade in the setting of
progressive CHF improves LV pump function and is accom-
panied by beneficial effects on vascular resistive properties and
adrenergic tone. Second, the findings of the present study
suggest that the beneficial hemodynamic effects reported in
both experimental and clinical studies of CHF following ad-
ministration of a nonspecific ET receptor antagonist (11,29,31)
are mediated primarily through the ETA receptor subtype.
Finally, the results from the present study provide evidence to
suggest that ETA receptor activation contributes to the con-
tinued progression of LV dysfunction in the setting of CHF
and that ETA receptor blockade may provide favorable effects
in this developing disease process.
The authors wish to acknowledge the dedicated efforts of Michael Taylor and
Sonya Noor for their assistance with the preliminary dose determination studies.
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